Back to results
US 2023/0144841 A1Published application
Inhibitors of fibroblast activation protein
AssigneePraxis Biotech LLC
InventorsBrahmam PUJALA, Dayanand PANPATIL, Sebastian BERNALES, Sebastian BELMAR, Gonzalo Andrés URETA DÍAZ
Life of this patent
Estimating the term…
Abstract
Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.
Claims19
A compound of formula (A):
- a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, wherein:
- R is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 3- to 12-membered heterocyclyl, 5- to 10-membered heteroaryl, or C6-C14 aryl, wherein the C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 3- to 12-membered heterocyclyl, 5- to 10-membered heteroaryl, and C6-C14 aryl of R are independently optionally substituted by Rd;
- RM is hydrogen or optionally substituted C1-C6 alkyl;
- m is 0, 1, 2, 3, or 4;
- n is 0, 1, 2, 3, or 4,
- wherein m+n is 1, 2, 3, or 4;
- X is —C(═O)—, —O—, —CH(OH)—, —S—, —S(═O)—, or —S(═O)2—;
- Y is
- wherein:
- the wavy line represents the point of attachment to the rest of the molecule,
- s is 1, 2, 3, or 4,
- R11 and R12 are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C4-C8 cycloalkenyl, 3- to 12-membered heterocyclyl, 5- to 10-membered heteroaryl, C6-C14 aryl, halogen, cyano, —OR14, —NR15R16, —SR14, —NO2, —C═NH(OR14), —C(O)R14, —OC(O)R14, —C(O)OR14, —C(O)NR15R16, —NR14C(O)R15, —NR14C(O)OR15, —NR14C(O)NR15R16, —S(O)R14, —S(O)2R14, —NR14S(O)R15, —NR14S(O)2R15, —S(O)NR15R16, —S(O)2NR15R16, or —P(O)(OR15)(OR16), wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C4-C8 cycloalkenyl, 3- to 12-membered heterocyclyl, 5- to 10-membered heteroaryl, and C6-C14 aryl of R11 and R12 are each independently optionally substituted by one or more of RL;
- each R13 is independently C2-C6 alkenyl, C2-C6 alkynyl, —NR15R16, —NO2, —C═NH(OR14), —C(O)R14, —OC(O)R14, —C(O)OR14, —C(O)NR15R16, —NR14C(O)R15, —NR14C(O)OR15, —NR14C(O)NR15R16, —S(O)R14, —S(O)2R14, —NR14S(O)R15, —NR14S(O)2R15, —S(O)NR15R16, —S(O)2NR15R16, or —P(O)(OR15)(OR16), wherein the C2-C6 alkenyl, and C2-C6 alkynyl of R13 are each independently optionally substituted by one or more RL;
- each R14 is independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, 5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, 5- to 10-membered heteroaryl, and 3- to 12-membered heterocyclyl of R14 are independently optionally substituted by halogen, —OH, oxo, cyano, or C1-C6 alkyl optionally substituted by halogen, —OH, or oxo;
- R15 and R16, independently of each other and independently at each occurrence, are hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, 5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, 5- to 10-membered heteroaryl, and 3- to 12-membered heterocyclyl of R15 and R16 are independently optionally substituted by halogen, —OH, oxo, cyano, or C1-C6 alkyl, optionally substituted by halogen, —OH, or oxo,
- or R15 and R16 are taken together with the atom to which they are attached to form a 3- to 6-membered heterocyclyl optionally substituted by halogen, oxo, cyano, or C1-C6 alkyl optionally substituted by halogen, —OH, or oxo;
- Rd, independently at each occurrence, is halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, 5- to 10-membered heteroaryl, 3- to 12-membered heterocyclyl, —OR14, —NR15R16, cyano, or nitro;
- and
- each RL is independently halogen, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C6-C14 aryl, 5- to 10-membered heteroaryl, 3- to 12-membered heterocyclyl, —C(O)R14, —OC(O)R14, —C(O)OR14, —C(O)NR15R16, —NR14C(O)R15, —NR14C(O)OR15, —NR14C(O)NR15R16, —S(O)R14, —S(O)2R14, —NR14S(O)R15, —NR14S(O)2R15, —S(O)NR15R16, —S(O)2NR15R16, —P(O)(OR15)(OR16), —NR15R16, cyano, oxo, or nitro, wherein (1) the C1-C6 alkoxy is optionally substituted by halogen, —OH, oxo, cyano, C1-C6 alkoxy, or C1-C6 alkyl optionally substituted by halogen, —OH, or oxo, (2) the C1-C6 alkyl is optionally substituted by 5- to 10-membered heteroaryl or 3- to 12-membered heterocyclyl, wherein the 3- to 12-membered heterocyclyl is further optionally substituted by C1-C6 alkyl, (3) the 5- to 10-membered heteroaryl is optionally substituted by oxo, and (4) the C3-C8 cycloalkenyl is optionally substituted by halogen, —OH, oxo, cyano, C1-C6 alkoxy, or C1-C6 alkyl.
16 more elements
(canceled)
A compound selected from the group consisting of
- or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof.
-38. (canceled)
Dependencies are inferred from the claim text.